Posted by Michael Wonder on 08 Sep 2022
Silence Therapeutics announces FDA fast track designation for SLN124, a novel investigational siRNA therapy for the treatment of polycythemia vera
8 September 2022 - Designation provides potential for expedited drug development path.
Silence Therapeutics today announced that the U.S. FDA has granted fast track designation to SLN124, a novel siRNA targeting the TMPRSS6 gene, for the treatment of polycythemia vera.
